Association Between Interleukin-12 and Sarcopenia

Yuan-Yuei Chen  
Tri-Service General Hospital

Tung-Wei Kao  
Tri-Service General Hospital

Yi-Lin Chiu  
National Defense Medical Center

Tao-Chun Peng  
Tri-Service General Hospital

Hui-Fang Yang  
Tri-Service General Hospital

Wei-Liang Chen (✉ weiliang0508@gmail.com)  
Department of Biochemistry, National Defense Medical Center, Taiwan, Republic of China.

Research Article

Keywords: gender, sarcopenia, IL-12, TGF-β, macrophage

DOI: https://doi.org/10.21203/rs.3.rs-144576/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Emerging studies have proposed that cytokines secreted following macrophage polarization may contribute to skeletal muscle aging. The current study primarily aimed to determine whether these cytokines have impact on the progression of sarcopenia in an elderly population.

Methods: Overall, 120 elderly adults aged 65 years and older who underwent health examinations from 2015 to 2019 were included in this retrospective study. Sarcopenia was based on the criteria proposed by the European Working Group on Sarcopenia in Older People in 2019. Macrophages and cytokines datasets were obtained from Gene Expression Omnibus (GEO) database. Comprehensive assessments were performed for muscle strength, muscle mass, gait speed, tumor growth factor-β (TGF-β), and interleukin-12 (IL-12). Thereafter, the association between sarcopenia and cytokines were analyzed using regression models.

Results: Low muscle strength and low speed gait were negatively associated with IL-12 [β: -8.96 (95%CI: -14.12, -3.79) and -7.16 (95%CI: -12.54, -1.78), respectively]. Participants with more sarcopenia components and more severe sarcopenia had lower IL-12 (P for trend < 0.001). Conversely, more sarcopenia components were associated with increased TGF-β (P for trend < 0.05). A definite diagnosis of sarcopenia was associated with decreased IL-12 and increased TGF-β with β of -8.96 (95%CI: -14.12, -3.79) and 147.75 (95%CI: 36.27, 259.23). Furthermore, increased IL-12 levels were significantly associated with reduced occurrence of sarcopenia with and odd ratio (OR) of 0.36 (95%CI: 0.15-0.834).

Conclusion: Our findings on the relationship between cytokines and age-related muscle loss showed that IL-12 may be an early diagnosis indicator for sarcopenia in the elderly population.

Introduction

Skeletal muscle aging, characterized by muscle mass loss, fibrosis, fat infiltration and other tissue modifications that causes a reduction in the force generated, has been associated with multiple adverse health outcomes, including loss of mobility, frailty, and sarcopenia[1–3]. Age-related muscle loss is caused by the imbalance between damage and repair processes at the molecular and myocellular levels[4–6]. Inflammation is an important contributor to the pathology of diseases implicated in age-related skeletal muscle dysfunction[7]. According to numerous studies, increases with age, as indicated by higher systemic concentrations of cytokines and acute-phase proteins[2, 8], greater basal cytokine production by peripheral blood mononuclear cells in vitro[9], and prolonged inflammatory reactions to infectious challenge in vivo[10, 11].

Macrophage polarization is a process by which macrophages adopt different functional programs in response to environmental signals such as cytokine milieu alterations, microbial ligands, and immune complexes[12]. Mounting evidence has proposed that macrophage polarization promtes diverse physiological processes within the skeletal muscle, including myogenic differentiation, fibrosis, and revascularization[13–15]. Moreover, emerging findings have suggested that M1 macrophages decline with aging although M2 macrophages are predominant in human skeletal muscle[16]. According to their specific functions, macrophages can be generally categorized into M1 and M2 subtypes, which produce pro-inflammatory and anti-inflammatory cytokines, respectively[17]. M1 macrophages secrete tumor necrosis factor, interleukin-1 (IL-
1), IL-10, IL-12, IL-23 and IL-6, whereas M2 macrophages secrete tumor growth factor-β (TGF-β) and IL-1 receptor antagonist. The present hypothesized that macrophages might affect the development of sarcopenia. Therefore, this cross-sectional study aimed to investigate the relationships between different macrophage polarization and sarcopenia in an aging population in Taiwan.

**Materials And Methods**

**Study design and participant recruitment**

Overall, 120 elderly participants aged 65 years and older who had undergone health checkups at Tri-Service General Hospital (TSGH), Taiwan, from 2015 to 2019 were included in this cross-sectional study. Questionnaires were used to obtain demographic information and muscle mass, muscle strength, and physical performance measurements, as well as laboratory examinations were performed. Thereafter, participants were categorized into four groups based on the number of sarcopenia components (component 0 = 36; component 1 = 36; component 2 = 32; component 3 = 16). TGF-β and IL-12 were then examined to explore their potential relationship with sarcopenia components. All analytic procedures were conducted in accordance with the TSGH guidelines. Our study was approved by the Institutional Review Board of TSGH, Taiwan, and participants provided informed consent prior to enrollment.

**Analysis of macrophage and cytokine datasets from Gene Expression Omnibus database**

Recent reviews evaluating immune cell populations and muscle differentiation have shown that macrophages and their secreted cytokines were strongly correlated with muscle aging. Macrophages are mainly polarized into M1 and M2, with M1 being more active in the skeletal muscle of young adults, and M2 playing an important role in the process of muscle tissue fibrosis and aging. To preliminarily assess the association between M1 and M2 macrophage activity in muscle tissues and adult age, GSE154846, a database of age-related gene expressions in adult skeletal muscle, was used. Approximately 500 samples of skeletal muscle from adults of different ages from GSE154846 was scored using Gene Set Variation Analysis (GSVA) scoring strategy based on published molecular signatures generated from M1 or M2 related differentially expressed genes[18]. Age-specific group comparisons, the young or middle-aged adult population had significantly higher GSVA scores representing M1 in their muscle tissue than the older population. In contrast, as expected, the GSVA scores for M2 increased significantly with age (Fig. 1).

**Sarcopenia diagnosis**

The revised operational definition proposed by the 2019 European Working Group on Sarcopenia in Older People (EWGSOP2)[19], identifies low muscle strength as the primary criterion for sarcopenia. Specifically, the aforementioned guideline demonstrates how to diagnose and evaluate severity in clinical practice. Accordingly, sarcopenia is suspected when low muscle strength is observed and is subsequently diagnosed when low skeletal muscle mass is evident. Meanwhile, severe sarcopenia is considered when low physical performance and two other criteria are observed. During the health checkups,
muscle strength was measured through hand grip strength using an analog isometric dynamometer, while muscle quality or quantity was estimated through the skeletal mass index (SMI) using a BIA (InBody720, Biospace, Inc., Cerritos, CA, USA). Physical performance was measured using the 6-m walking distance. Based on the recommendations provided by EWGSOP2, the cutoff points for hand grip strength were 27.0 and 16 kg for men and women, respectively[20]. Those for SMI were 7.0 and 6.0 kg/m2 for men and women, respectively[21], and those for gait speed were 0.8 m/s for both men and women[22].

Cytokines

To determine disclose the underlying pathophysiological mechanisms, the following cytokines were analyzed based on the standard procedures indicated in the manufacturer's instructions. TGF-β (Cedar Valley Drive, Westlake Village, CA, USA) and IL-12 (Cedar Valley Drive, Westlake Village, CA, USA) were assayed using a competitive enzyme-linked immunoassay. The lower detection limits for TGF-β and IL-12 were 15.6 and 7.8 pg/mL, respectively. The coefficients of variation for the four assays ranged from 5–10% during the sample analysis period.

Study variables

Demographic data, such as age, gender, and smoking history, were obtained from participants’ self-reported questionnaires. Information on comorbidities, such as hypertension, diabetes mellitus, myocardial infarction, angina, coronary artery disease, chronic obstructive pulmonary disease, and arthritis, was also collected from the participants.

Statistical analysis

The Statistical Package for the Social Sciences, version 22.0 (SPSS Inc., Chicago, IL, USA), for Windows was used for all statistical analyses. All estimates were performed based on the sample weights to represent the total population of Taiwan and were adjusted for the complex sample design of the survey. Significant differences among sarcopenia component groups were determined using the Pearson's chi-square test. A two-sided p value of < 0.05 was considered statistically significant. Associations between cytokines and sarcopenia, as well as components thereof, were analyzed using a linear regression model. Moreover, relationships between cytokines and odds ratios (ORs) for sarcopenia were analyzed using a logistic regression model. Thereafter, to adjust for age, sex, smoking history, and number of comorbidities, multivariate analysis was conducted. Receiving operating characteristic (ROC) curve analysis was used to calculate the optimal cutoff points for cytokines as well as the area under the ROC (AUROC) and the corresponding 95% confidence intervals (CI) to determine the associations between cytokines and sarcopenia.

Results

Association between cytokines and macrophage polarization in the GEO database

M1 or M2 macrophages secrete distinct cytokines that affect the growth and regeneration of skeletal muscle, respectively. To evaluate which cytokine was significantly associated with the GSVA score of a specific
macrophage, correlations between the aforementioned cytokine-related pathways after GSVA scoring via the NIH PID pathway and BIOCARTA databases were further analyzed.

Figure 2 shows that the GSVA score of the IL12 pathway significantly differed among adult populations of different ages and was significantly positively correlated with M1 macrophage score. In contrast, the GSVA score of the TGFB pathway was significantly negatively correlated with the M1 macrophage GSVA score, although the results were similar to those IL-12 across age groups. Other cytokines were either not significantly correlated with M1/M2 GSVA scores across age groups or were not significantly correlated with M1/M2 GSVA scores.

**Study population characteristics**

All participants were categorized into four groups based on the number of sarcopenia components, and Table 1 summarizes the demographic characteristics of participants. Each group had a mean age 72.29 ± 5.46, 72.36 ± 6.71, 75.98 ± 8.77, 82.44 ± 8.74 years, respectively. Participants with more sarcopenia components had significantly lower grip strength, physical performance, and skeletal muscle mass (p < 0.001). Moreover, those with severe sarcopenia had the lowest IL-12 levels and highest TGF-β levels among the groups.
Table 1
Characteristics of Study Population

| Variable         | Components of sarcopenia | 0          | 1          | 2          | 3          | P value |
|------------------|--------------------------|------------|------------|------------|------------|---------|
| Continuous variable (SD) |                      |            |            |            |            |         |
| Age (years)      |                          | 72.29 (5.46)| 72.36 (6.71)| 75.98 (8.77)| 82.44 (8.74)| < 0.001 |
| Grip strength    |                          | 30.08 (8.69)| 25.30 (7.86)| 19.25 (8.09)| 15.62 (5.90)| < 0.001 |
| SMI              |                          | 7.11 (0.89 )| 6.08 (0.99 )| 5.76 (0.81 )| 5.88 (0.67 )| < 0.001 |
| Gait speed       |                          | 1.20 (0.18 )| 1.19 (0.31 )| 0.88 (0.26 )| 0.59 (0.16 )| < 0.001 |
| Comorbidity No.  |                          | 0.78 (0.96 )| 0.89 (1.19 )| 1.03 (1.15 )| 1.06 (1.06 )| 0.746   |
| IL-12            |                          | 46.08 (12.94)| 45.05 (14.28)| 40.11 (7.66)| 33.71 (10.59)| 0.003   |
| TGF-β            |                          | 139.34 (145.36)| 149.21 (173.09)| 271.32 (361.31)| 289.69 (381.05)| 0.072   |
| Categorical variable (%) |                    |            |            |            |            |         |
| Gender (male)    |                          | 18 (50.0 )  | 20 (55.6 )  | 22 (68.8 )  | 7 (43.8 )  | 0.674   |
| Smoking          |                          | 11 (31.4 )  | 9 (25 )    | 4 (12.5 )  | 2 (12.5 )  | 0.043   |
| HTN              |                          | 15 (41.7 )  | 10 (27.8 )  | 13 (40.6 )  | 10 (62.5 )  | 0.219   |
| DM               |                          | 6 (16.7 )   | 6 (16.7 )   | 5 (15.6 )   | 1 (6.3 )   | 0.428   |
| MI               |                          | 0 (0.0 )    | 1 (2.8 )    | 0 (0.0 )    | 0 (0.0 )    | 0.821   |
| Angina           |                          | 0 (0.0 )    | 0 (0.0 )    | 0 (0.0 )    | 0 (0.0 )    | -       |
| CAD              |                          | 3 (8.3 )    | 3 (8.3 )    | 3 (9.4 )    | 2 (12.5 )   | 0.661   |
| COPD             |                          | 2 (5.6 )    | 2 (5.6 )    | 2 (6.3 )    | 0 (0.0 )    | 0.570   |
| Arthritis        |                          | 2 (5.6 )    | 10 (27.8 )  | 10 (31.3 )  | 4 (25.0 )   | 0.031   |

SMI, skeletal muscle mass index; S&S time, stand up & sit down time; HTN, hypertension; DM, diabetes mellitus; MI, myocardial infarction; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease

Association between sarcopenia and cytokines

Table 2 presents the associations between cytokines and sarcopenia components, number of sarcopenia components, and definite diagnosis of sarcopenia. Accordingly, the univariate model showed that low muscle strength, muscle mass, and speed gait were associated with decreased IL-12 levels with $\beta$ of -6.69 (95%CI: -11.25, -2.13), -4.68 (95%CI: -9.25, -0.10), and -6.68 (95%CI: -11.74, -1.82), respectively. After adjusting for variables, low muscle strength and low speed gait remained significantly associated with decreased IL-12 levels with $\beta$ of -8.96 (95%CI: -14.12, -3.79) and -7.16 (95%CI: -12.54, -1.78). Participants with more sarcopenia components had significantly lower IL-12 with $\beta$ of -4.55 (P for trend < 0.001). Confirmed and severe sarcopenia were associated with decreased IL-12 with $\beta$ of -7.51 (95%CI: -13.94, -1.07) and -14.03
(95%CI: -21.36, -6.69) after full adjustment. Conversely, low muscle strength was associated with increased TGF-β levels with β of 147.75 (95%CI: 36.27, 259.23). More sarcopenia components were significantly associated with higher TGF-β with β of 52.17 (P for trend < 0.05). Confirmed sarcopenia was associated with increased TGF-β with β of 190.10 (95%CI: 50.08, 330.13). Moreover, a definite diagnosis of sarcopenia, including confirmed and severe subtypes, was significantly associated with decreased IL-12 and increased TGF-β with β of -8.96 (95%CI: -14.12, -3.79) and 147.75 (95%CI: 36.27, 259.23) after full adjustment.
Table 2
Association between cytokines, components of sarcopenia, number of sarcopenia, and diagnosis of sarcoepenia

| Variables                           | IL-12                  | TGF-β                  |
|-------------------------------------|------------------------|------------------------|
|                                     | Crude β coefficients   | Adjusted β coefficients| Crude β coefficients | Adjusted β coefficients |
|                                     | (95% CI)               | (95% CI)               | (95% CI)             | (95% CI)               |
|                                     | P Value                | P Value                | P Value              | P Value                |
| Components of sarcopenia            |                        |                        |                      |                        |
| Low speed gait                      | -6.68                  | -7.16                  | 0.010                | 49.92                  | 0.374                  |
|                                     | (-11.74, -1.82)        | (-12.54, -1.78)        | 0.010                | (-60.81, 160.65)       | 0.374                  |
| Low muscle mass                     | -4.68                  | -4.48                  | 0.062                | 84.32                  | 0.097                  |
|                                     | (-9.25, -0.10)         | (-9.18, 0.21)          | 0.062                | (-15.63, 184.27)       | 0.097                  |
| Low muscle strength                 | -6.69                  | -8.96                  | < 0.001              | 134.68                 | 0.008                  |
|                                     | (-11.25, -2.13)        | (-14.12, -3.79)        | 0.001                | (35.42, 233.93)        | 0.008                  |
| Number of sarcopenia                |                        |                        |                      |                        |                        |
| 1                                   | -1.05                  | -1.11                  | 0.698                | 9.87                   | 0.877                  |
|                                     | (-6.68, 4.58)          | (-6.75, 4.54)          | 0.698                | (-116.12, 135.86)      | 0.877                  |
| 2                                   | -5.99                  | -7.22                  | 0.019                | 131.98                 | 0.047                  |
|                                     | (-11.79, -0.18)        | (-13.25, -1.20)        | 0.019                | (2.05, 261.92)         | 0.047                  |
| 3                                   | -12.39                 | -14.77                 | < 0.001              | 150.35                 | 0.063                  |
|                                     | (-19.55, -5.22)        | (-22.61, -6.94)        | 0.001                | (8.27, 308.98)         | 0.063                  |
| P for trend                         | -3.90                  | < 0.001                | -4.55                | 59.07                  | 0.015                  |
|                                     |                        |                        | < 0.001              | 52.17                  | 0.015                  |
| Severity of sarcopenia              |                        |                        |                      |                        |                        |
| Probable                            | -1.50                  | -4.55                  | 0.291                | 46.86                  | 0.615                  |
|                                     | (-9.55, 6.54)          | (-13.05, 3.95)         | 0.291                | (-137.09, 230.81)      | 0.615                  |
| Confirmed                           | -5.52                  | -7.51                  | 0.023                | 169.73                 | 0.014                  |
|                                     | (-11.66, 0.63)         | (-13.94, -1.07)        | 0.023                | (35.54, 303.92)        | 0.014                  |
| Severe                              | -11.32                 | -14.03                 | < 0.001              | 142.45                 | 0.052                  |
|                                     | (-17.91, -4.74)        | (-21.36, -6.69)        | 0.001                | (-1.35, 286.25)        | 0.052                  |
| Diagnosis of sarcopenia (confirmed  |                        |                        |                      |                        |                        |
| and severe)                         | a Adjusted covariates: |                        |                      |                        |                        |
| Fully adjusted: age, sex, smoking   |                        |                        |                      |                        |                        |
| history, number of comorbidities    |                        |                        |                      |                        |                        |
Association between cytokines and occurrence of sarcopenia

To determine the ability of cytokines to predict the occurrence of sarcopenia, the optimal cutoff points for IL-12 and TGF-β were calculated using ROC analysis (Fig. 3). Accordingly, IL-12 had an AUROC of 0.64 (95%CI: 0.53–0.74) with an optimal cutoff point of 41.80 (sensitivity: 53%; specificity: 73%). Meanwhile, TGF-β had an AUROC of 0.60 (95%CI: 0.49–0.72) with an optimal cutoff point of 92.09 (sensitivity: 66%; specificity: 56%) (Supplementary Table 1).

Figure 4 shows the relationships between the occurrence of sarcopenia and continuous cytokine levels and their cutoff points. IL-12 and age were associated with the occurrence of sarcopenia with OR of 0.969 (95%CI: 0.939-1.000) and 1.061 (95%CI: 1.003–1.121) in the unadjusted model. After full adjustment, IL-12 remained significantly associated with the occurrence of sarcopenia with OR of 0.969 (95%CI: 0.938-1.000). However, no significant association was noted between TGF-β and sarcopenia. Regarding cytokine cutoff points, IL-12 was inversely associated with the occurrence of sarcopenia with OR of 0.356 (95%CI: 0.157–0.807) (Fig. 5), while TGF-β was positively associated with the occurrence of sarcopenia with OR of 2.443 (95%CI: 1.080–5.527) in the unadjusted model. After full adjustment for variables, IL-12 remained significantly associated with the occurrence of sarcopenia with OR of 0.356 (95%CI: 0.151–0.838).

Discussion

The present study found that the cytokine levels might affect the number of sarcopenia components and sarcopenia severity. Accordingly, our results showed that, among elderly participants, more sarcopenia components were associated with decreased IL-12 and increased TGF-β levels. We speculate that these cytokines might have been partly released during macrophage polarization into M1 and M2 subtypes, which are involved in pro-inflammatory and anti-inflammatory activities, respectively. To the best of our knowledge, the present study was the first to explore the relationships between cytokines and sarcopenia in a Taiwanese elderly population.

TGF-β has been proposed to induce skeletal muscle atrophy and fibrosis by regulating the activity of skeletal muscle satellite cell[23]. Moreover, TGF-β has been suggested to lower muscle regeneration by inhibiting muscle cell differentiation and proliferation via the Smad-3 signaling system, which has been shown to prevent positive regulators of muscle cell differentiation, including MyoD and myogenin[24]. Excessive TGF-β production has been considered the main cause of progressive tissue fibrosis and scar formation, leading to muscle loss and impaired muscle function[25]. Moreover, studies have suggested that TGF-β plays a role in muscle impairment and fibrosis accompanying the aging process. Our findings are consistent with those
presented in previous studies showing that sarcopenia is significantly associated with increased TGF-β levels[26].

IL-12 is a pro-inflammatory cytokine that promotes T cell proliferation and cytotoxic activity[27]. Unfortunately, limited studies have been available regarding the role of IL-12 in myogenic differentiation. Romanazzo et al. demonstrated that IL-12 overexpression in C2C12 mouse skeletal muscle cells enhanced the myogenic differentiation process[28]. IL-12 has been a well-known risk factor for Alzheimer's disease and cognitive aging[29, 30]. A population-based study of Taiwanese elderly participants, suggested that IL-12-associated genes caused the etiological changes observed during cognitive aging[31]. Previous studies have also proposed a connection between IL-12 and physical activity. Accordingly, endurance exercise has been associated with the induction of Th2 cytokines, including IL-4 and IL-12[32], while Suzuki et al. demonstrated that IL-12 concentration significantly increased after maximal exercise[33]. Moreover, a retrospective study of 16 men who participated in a running program showed that intense exercise enhances IL-12 levels in peripheral blood mononuclear cells[34]. The present study found that lower IL-12 levels were associated with a higher occurrence of sarcopenia. Given the aforementioned findings, we speculate that patients with increased IL-12 levels may have better muscle strength and physical performance, as well as lower incidences of sarcopenia. Further experiments will be necessary to clarify the function of IL-12 in human skeletal muscle and the molecular mechanisms underlying its action.

Cui et al. had reported the role of macrophage polarization in skeletal muscle metabolism associated with aging, which is involved in the distinct macrophage function[16]. Impaired macrophage activity during aging has been suggested to promote deterioration in satellite cell function and muscle regeneration[35]. One study observed that the resting muscles of aged mice had increased M2 macrophages, accompanied by increased skeletal muscle fibrosis[36]. Meanwhile, a human study showed that older patients had higher gene expression of M2 macrophages compared to the younger patients, suggesting an increase in the proinflammatory process with age[37]. Moratal et al. demonstrated that M2 macrophages induced adipogenesis through fibro-adipogenic progenitors[38]. By promoting fibrosis and fat infiltration, which are major features of skeletal muscle aging, macrophage polarization, especially M2 macrophages, may play an important role in the altered skeletal muscle function, and sarcopenia.

Some limitations in the present study are worth noting. First, the cross-sectional design of this study prevented the identification of causal relationships between cytokines and sarcopenia. Therefore, longitudinal studies are needed to explore whether cytokines can be utilized for the early diagnosis and evaluation of therapeutic interventions in sarcopenia. Second, flow cytometry, which measures specific protein expressions, has been the standard method for identifying macrophages. However, given that only a few macrophages were detected in the study samples, cytokines were obtained from participants’ blood samples to indicate macrophage activation. Next, considering that cytokines are potent mediators across various inflammatory states and age-related diseases, their measurements might have been affected by physiological and pathological changes. Therefore, macrophage polarization can only be an indirect predictor for evaluating muscle differentiation and sarcopenia. Finally, the sensitivity and specificity values are relatively low in the present study. The sensitivity and specificity of a quantitative test are dependent on the cutoff point above or below which the test is positive. If the cutoff point is raised, there are fewer false positives but more false negatives that the test is highly specific but not very sensitive.
The current study found that the number of sarcopenia components and sarcopenia severity were associated with plasma cytokines levels among older individuals. Furthermore, IL-12 had been found to be associated with the occurrence of sarcopenia, suggesting its potential as a muscle quality indicator for predicting outcomes of age-associated muscle loss. The combination of clinical practice and biomarker assessment in evaluating muscle quality may be essential for the early diagnosis of sarcopenia. Moreover, determining whether IL-12 can become a novel biological target for preventive and therapeutic interventions will be interesting. Nevertheless, the potential mechanisms through which macrophage function affects aging skeletal muscle remain unclear. Further studies are required to characterize the function of these cytokines and provide a basis for the better modulation of their signaling in therapeutic approaches.

Declarations

**Ethics approval and consent to participate:** All procedures were conducted in accordance with the guidelines of TSGH. We have obtained patient permission before enrollment by asking them to complete a written informed consent, and approval for the study was granted by the Institutional Review Board of TSGH, Taiwan.

**Consent for publication:** not applicable.

**Availability of data and materials:** The datasets generated and analyses performed during the current study are not publicly available due to the consent requirement of participants, but sex and age decade-stratified descriptive data are available from the corresponding author on reasonable request.

**Competing interests:** The authors declared that they had no competing interests. **Funding:** This study was supported by the Ministry of Science and Technology (MOST 108-2314-B-016 -032), Taiwan, ROC.

**Authors' contributions:** YY.C. contributed to the design of the study, was responsible for the management and retrieval of data, contributed to initial data analysis and interpretation, drafted the initial manuscript. YY.C., TW.K., YL.C., TC.P., HF.Y., WL.C. decided upon the data collection methods. YY.C. and WL.C. were also responsible for the data analysis decisions. WL.C. conceptualized and designed the study, supervised all aspects of the study, critically reviewed and revised the manuscript, and approved the final manuscript as submitted.

**Acknowledgements:** None.

**References**

1. Janssen I: Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. *J Am Geriatr Soc* 2006, 54(1):56-62.

2. Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, Guralnik JM, Longo DL: The origins of age-related proinflammatory state. *Blood* 2005, 105(6):2294-2299.

3. Tieland M, Trouwborst I, Clark BC: Skeletal muscle performance and ageing. *J Cachexia Sarcopenia Muscle* 2018, 9(1):3-19.
4. Hepple RT, Rice CL: Innervation and neuromuscular control in ageing skeletal muscle. *J Physiol* 2016, 594(8):1965-1978.

5. Saini J, McPhee JS, Al-Dabbagh S, Stewart CE, Al-Shanti N: Regenerative function of immune system: Modulation of muscle stem cells. *Aging Res Rev* 2016, 27:67-76.

6. Gonzalez-Freire M, de Cabo R, Studenski SA, Ferrucci L: The Neuromuscular Junction: Aging at the Crossroad between Nerves and Muscle. *Front Aging Neurosci* 2014, 6:208.

7. Londhe P, Guttridge DC: Inflammation induced loss of skeletal muscle. *Bone* 2015, 80:131-142.

8. Wikby A, Nilsson BO, Forsey R, Thompson J, Strindhall J, Lofqren S, Ernurudh J, Pawelec G, Ferguson F, Johansson B: The immune risk phenotype is associated with IL-6 in the terminal decline stage: findings from the Swedish NONA immune longitudinal study of very late life functioning. *Mech Ageing Dev* 2006, 127(8):695-704.

9. Roubenoff R, Harris TB, Abad LW, Wilson PW, Dallal GE, Dinarello CA: Monocyte cytokine production in an elderly population: effect of age and inflammation. *J Gerontol A Biol Sci Med Sci* 1998, 53(1):M20-26.

10. Krabbe KS, Bruunsgaard H, Hansen CM, Moller K, Fonsmark L, Qvist J, Madsen PL, Kronborg G, Andersen HO, Skinhoj P et al: Ageing is associated with a prolonged fever response in human endotoxemia. *Clin Diagn Lab Immunol* 2001, 8(2):333-338.

11. Bruunsgaard H, Skinhoj P, Qvist J, Pedersen BK: Elderly humans show prolonged in vivo inflammatory activity during pneumococcal infections. *J Infect Dis* 1999, 180(2):551-554.

12. Wynn TA, Chawla A, Pollard JW: Macrophage biology in development, homeostasis and disease. *Nature* 2013, 496(7446):445-455.

13. Tidball JG: Mechanisms of muscle injury, repair, and regeneration. *Compr Physiol* 2011, 1(4):2029-2062.

14. Dufresne SS, Frenette J, Dumont NA: [Inflammation and muscle regeneration, a double-edged sword]. *Med Sci (Paris)* 2016, 32(6-7):591-597.

15. Smith C, Kruger MJ, Smith RM, Myburgh KH: The inflammatory response to skeletal muscle injury: illuminating complexities. *Sports Med* 2008, 38(11):947-969.

16. Cui CY, Driscoll RK, Piao Y, Chia CW, Gorospe M, Ferrucci L: Skewed macrophage polarization in aging skeletal muscle. *Aging Cell* 2019, 18(6):e13032.

17. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM: M-1/M-2 macrophages and the Th1/Th2 paradigm. *J Immunol* 2000, 164(12):6166-6173.

18. Foroutan M, Bhuvan DD, Lyu R, Horan K, Cursons J, Davis MJ: Single sample scoring of molecular phenotypes. *BMC Bioinformatics* 2018, 19(1):404-404.

19. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA et al: Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019, 48(1):16-31.

20. Dodds RM, Syddall HE, Cooper R, Benzeval M, Deary IJ, Dennison EM, Der G, Gale CR, Inskip HM, Jagger C et al: Grip strength across the life course: normative data from twelve British studies. *PLoS One* 2014, 9(12):e113637.

21. Gould H, Brennan SL, Kotowicz MA, Nicholson GC, Pasco JA: Total and appendicular lean mass reference ranges for Australian men and women: the Geelong osteoporosis study. *Calcif Tissue Int* 2014, 94(4):363-
22. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM et al: Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010, 39(4):412-423.

23. Mendias CL, Gumucio JP, Davis ME, Bromley CW, Davis CS, Brooks SV: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve 2012, 45(1):55-59.

24. Carlson ME, Hsu M, Conboy IM: Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature 2008, 454(7203):528-532.

25. Ismaeel A, Kim J-S, Kirk JS, Smith RS, Bohannon WT, Koutakis P: Role of Transforming Growth Factor-β in Skeletal Muscle Fibrosis: A Review. International journal of molecular sciences 2019, 20(10):2446.

26. Kim J, Lee J: Role of transforming growth factor-β in muscle damage and regeneration: focused on eccentric muscle contraction. J Exerc Rehabil 2017, 13(6):621-626.

27. Trinchieri G: Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995, 13:251-276.

28. Romanazzo S, Forte G, Morishima K, Taniguchi A: IL-12 involvement in myogenic differentiation of C2C12 in vitro. Biomater Sci 2015, 3(3):469-479.

29. Vom Berg J, Prokop S, Miller KR, Obst J, Kalin RE, Lopategui-Cabezas I, Wegner A, Mair F, Schipke CG, Peters O et al: Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nat Med 2012, 18(12):1812-1819.

30. Tan MS, Yu JT, Jiang T, Zhu XC, Guan HS, Tan L: IL12/23 p40 inhibition ameliorates Alzheimer’s disease-associated neuropathology and spatial memory in SAMP8 mice. J Alzheimers Dis 2014, 38(3):633-646.

31. Lin E, Kuo PH, Liu YL, Yang AC, Tsai SJ: Association and Interaction Effects of Interleukin-12 Related Genes and Physical Activity on Cognitive Aging in Old Adults in the Taiwanese Population. Front Neurol 2019, 10:1065.

32. Suzuki K: Cytokine Response to Exercise and Its Modulation. Antioxidants (Basel) 2018, 7(1):17.

33. Suzuki K, Nakaji S, Kurakake S, Totsuka M, Sato K, Kuriyama T, Fujimoto H, Shibusawa K, Machida K, Sugawara K: Exhaustive exercise and type-1/type-2 cytokine balance with special focus on interleukin-12 p40/p70. Exerc Immunol Rev 2003, 9:48-57.

34. Zamani A, Salehi I, Behzad M: Moderate Exercise Enhances the Production of Interferon-γ and Interleukin-12 in Peripheral Blood Mononuclear Cells. Immune Network 2017, 17:186.

35. Dort J, Fabre P, Molina T, Dumont NA: Macrophages Are Key Regulators of Stem Cells during Skeletal Muscle Regeneration and Diseases. Stem Cells International 2019, 2019:4761427.

36. Wang Y, Wehling-Henricks M, Samengo G, Tidball JG: Increases of M2a macrophages and fibrosis in aging muscle are influenced by bone marrow aging and negatively regulated by muscle-derived nitric oxide. Aging Cell 2015, 14(4):678-688.

37. Tam CS, Sparks LM, Johannsen DL, Covington JD, Church TS, Ravussin E: Low macrophage accumulation in skeletal muscle of obese type 2 diabetics and elderly subjects. Obesity (Silver Spring) 2012, 20(7):1530-1533.
38. Moratal C, Raffort J, Arrighi N, Rekima S, Schaub S, Dechesne CA, Chinetti G, Dani C: **IL-1β- and IL-4-polarized macrophages have opposite effects on adipogenesis of intramuscular fibro-adipogenic progenitors in humans.** In: *Sci Rep.* vol. 8; 2018: 17005.

**Figures**

![Flow chart of participants](image)

**Figure 1**

Flow chart of participants
Figure 2

Gene set variation analysis scoring of M1 and M2 signatures
Figure 3

Associations among different cytokines expressions, M1, and M2 signatures
Figure 4

Receiver operating characteristic curve analysis for optimal cutoff points of IL-12 (Figure 4A) and TGF-β (Figure 4B)

| Crude odds ratio (95%CI) | Adjusted odds ratio (95%CI) |
|-------------------------|-----------------------------|
| Age                     | 1.064 (1.001-1.132)         | IL-12                    | 0.969 (0.938-1.000) |
| Sex                     | 1.480 (1.066-1.687)         | TGF-β                    | 1.002 (0.999-1.004) |
| Smoking                 | 0.474 (0.192-1.174)         | IL-12 cutoff point       | 1.428 (1.477-4.276) |
| Comorbidity             | 1.135 (0.894-1.476)         | TGF-β cutoff point       | 0.680 (0.197-2.348) |
| IL-12                   | 0.909 (0.539-1.490)         |                           |                       |
| TGF-β                   | 1.002 (0.599-1.004)         |                           |                       |

Figure 5

Association between cytokines and the occurrence of sarcopenia

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- SupplementalTable.docx